Asset profile
PB-119
Peptide
Evidence outlook · lead readout
NCT04504396 · Type 2 Diabetes Mellitus (T2DM)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04504396: The study randomized 620 participants to PB-119 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c, a surrogate measure, and no results are posted to show whether the comparison favored PB-119.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.